Janssen Search
Search results
Johnson & Johnson to Obtain Rights to a Clinical-Stage Bispecific Antibody to Address Distinct Patient Needs in Atopic Dermatitis
May 28, 2024 The Company 1 enters agreement with Numab Therapeutics to acquire its wholly owned subsidiary 2 for the global rights to NM26, a Phase 2-ready investigational, first-in-class bispecific antibody targeting two clinically proven pathways in ...
How to Lead with Impact as Healthcare Manufacturers and Innovators in a Post-COVID World
How to Lead with Impact as Healthcare Manufacturers and Innovators in a Post-COVID World " Unprecedented times… Uncertain circumstances… Unlike anything we’ve seen before." We’ve all had more than our fill of those "un" phrases over ...
Johnson & Johnson’s Investigational TAR-200 Granted U.S. FDA Breakthrough Therapy Designation for the Treatment of High-Risk Non-Muscle-Invasive Bladder Cancer
Dec 04, 2023 United States Breakthrough Therapy Designation for Novel Targeted Releasing System Based on Results from Ongoing Phase 2b SunRISe-1 Study RARITAN, N.J., Dec. 4, 2023 – Johnson & Johnson announced today that the U.S. Food and Drug ...
Oncology Careers
Oncology Careers: What Kind of Mark Will You Make? Janssen’s Oncology organization fosters the passion within our people by developing their careers, creating a collaborative environment and unifying behind a common goal – to make a difference in the ...
Grant to Harvard Medical School
New Grant to Harvard Medical School to Combat Drug-Resistant Tuberculosis As part of its ongoing commitment to global public health, Janssen entered into a novel collaboration with Harvard Medical School in Cambridge, Massachusetts, to address critical ...
Innovating HIV Treatment and Prevention
Innovating HIV Treatment and Prevention Expanding Access to HIV Treatment is a Top Global Public Health Priority Janssen is exploring innovative applications of our HIV medicines to help address treatment and prevention outcomes in hard-to-reach areas by ...
Careers
Your future could be helping us make diseases a thing of the past. John Doe Title--> {{> organisms-social-buttons}} Learn more About Us At Janssen, our employees start each day driven by the belief that patients are waiting and there is no time to ...
ESMO 2021
LATEST NEWS RYBREVANT® (amivantamab-vmjw) Provides Higher Activity and Longer Duration of Response When Used in Combination with Lazertinib in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer Who Have Failed Osimertinib New Data on ...
ART GALLERY
ART GALLERY Since 2010, Janssen has been curating a robust art collection, featuring contributions by patients, caregivers, patient advocates, and even our own scientists. The common thread among all these artists is that each has been affected, in some ...
ASCO GU 2023
Welcome to the Janssen Oncology ASCO GU Virtual Newsroom Luca Dezzani, M.D. U.S. Vice President Medical Affairs, Solid Tumor Janssen Scientific Affairs, LLC Kiran Patel, M.D. Vice President Clinical Development, Solid Tumors Janssen Research & ...